Unilabs and Ibex are teaming up to make cancer diagnosis more accurate, timely, and targeted.
Per the new deal, Unilabs will deploy Ibex’s AI-powered, multi-tissue Galen platform in pathology labs across Europe. Backed by advanced machine learning algorithms, the platform evaluates tissue biopsies in real time to offer valuable insights on tumor grading and size.
Other notable features of the Galen include worklists for case prioritization and cancer heatmaps for increased diagnostic accuracy.
"This cutting-edge AI technology will help our teams quickly prioritise urgent cases, speed up diagnosis, and improve quality by adding an extra set of digital eyes," said Dr. Christian Rebhan, chief medical and operations officer at Unilabs.
Rebhan continued, "When it comes to cancer, the earlier you catch it, the better the prognosis – so getting us critical results faster will help save lives. The partnership with Ibex underlines Unilabs' pioneering role in digital pathology and represents yet another step in our ambition to become the most digitally enabled provider of diagnostic services in Europe."
Galen by Ibex is CE-marked for breast and prostate cancer detection. Unilabs will roll out Ibex's platform to 16 countries, starting with Sweden.
RELATED RESOURCE
DevOps: A view from the enterprise
What's driving DevOps, the impact of value stream management, and more
"Ibex is transforming cancer diagnosis with innovative AI solutions across the diagnostic pathway," said Joseph Mossel, chief executive officer (CEO) and co-founder of Ibex Medical Analytics.
"We are excited to partner with Unilabs to deploy our AI solutions and empower their pathologists with faster turnaround times and quality diagnosis. This cooperation follows a thorough evaluation of our technology at Unilabs, and demonstrates the robustness and utility of our platform for everyday clinical practice."
-
The Race Is On for Higher Ed to Adapt: Equity in Hyflex Learning -
Google faces 'first of its kind' class action for search ads overcharging in UKNews Google faces a "first of its kind" £5 billion lawsuit in the UK over accusations it has a monopoly in digital advertising that allows it to overcharge customers.
-
Cambridge-1 and the future of medicineCase Studies Nvidia’s first public supercomputer could change healthcare in the UK and around the world
-
NIH renews COVID research contract with PalantirNews Palantir will create a cloud-based data enclave to support COVID-19 research collaborations
-
Sensome’s AI-powered stroke guidewire begins human trials in AustraliaNews The trial adds to Sensome’s multicenter CLOT OUT study
-
Yext’s Find-a-Doc streamlines finding a doctor with AINews The platform provides smart suggestions to improve patients' pre-appointment experience
-
NeuPath and Cynergi will bring VR therapy to chronic pain managementNews NeuPath will integrate Cynergi’s VR program with its remote pain management platform
-
VEON's Beeline to bring mobile AI to health careNews Beeline will work with Sechenov Medical University to promote early diagnosis of life-threatening conditions
-
Qlarity Imaging teams with Blackford to improve breast MRI accuracyNews Qlairty will merge its AI-powered diagnostic software with Blackford’s centralized imaging platform
-
Oncotech launches the first-ever mobile cancer screening toolNews Oncotech's real-time cancer diagnostic tool lets you check for cancer right from your smartphone
